Education
About Us
Working with TipRanks
Follow Us
Mineralys Therapeutics, Inc. (MLYS)
NASDAQ:MLYS
MLYS Stock Chart & Stats
$38.02
-$0.99(-7.63%)
At close: 4:00 PM EST
$38.02
-$0.99(-7.63%)
Day’s Range― - ―
52-Week Range$8.24 - $44.80
Previous CloseN/A
Volume137.34K
Average Volume (3M)1.19M
Market Cap
$3.08B
Enterprise Value$560.64M
Total Cash (Recent Filing)$101.79M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.19
Next Earnings
Nov 10, 2025EPS Estimate
-0.61Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.66
Shares Outstanding77,569,695
10 Day Avg. Volume855,877
30 Day Avg. Volume1,188,335
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.18
Enterprise Value/Revenue16.49K
Enterprise Value/Gross Profit-62.29K
Enterprise Value/Ebitda-2.76
Forecast
1Y Price Target
$44.57Price Target Upside17.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-2.67
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessLorundrostat achieved robust absolute reduction in blood pressure in trials, standing out even greater in the context of Phase 3 competitor ASI data.
Financial SupportThe closing of an upsized $287.5M underwritten public offering of common stock, along with existing cash, supports pre-commercialization activities for lorundrostat and its ongoing clinical development.
Market PositioningLorundrostat is expected to be well-positioned as a third-line and fourth-line therapy, addressing the needs of tens of millions of uncontrolled hypertension patients.
Bears Say
Competitor AdvancementsAZN plans to file by YE, i.e., late 2026 approval and before MLYS, which is estimated to be H1:27.
Mineralys Therapeutics, Inc. News
MLYS FAQ
What was Mineralys Therapeutics, Inc.’s price range in the past 12 months?
Mineralys Therapeutics, Inc. lowest stock price was $8.24 and its highest was $44.80 in the past 12 months.
What is Mineralys Therapeutics, Inc.’s market cap?
Mineralys Therapeutics, Inc.’s market cap is $3.08B.
When is Mineralys Therapeutics, Inc.’s upcoming earnings report date?
Mineralys Therapeutics, Inc.’s upcoming earnings report date is Nov 10, 2025 which is in 2 days.
How were Mineralys Therapeutics, Inc.’s earnings last quarter?
Mineralys Therapeutics, Inc. released its earnings results on Aug 12, 2025. The company reported -$0.66 earnings per share for the quarter, beating the consensus estimate of -$0.739 by $0.079.
Is Mineralys Therapeutics, Inc. overvalued?
According to Wall Street analysts Mineralys Therapeutics, Inc.’s price is currently Undervalued.
Does Mineralys Therapeutics, Inc. pay dividends?
Mineralys Therapeutics, Inc. does not currently pay dividends.
What is Mineralys Therapeutics, Inc.’s EPS estimate?
Mineralys Therapeutics, Inc.’s EPS estimate is -0.61.
How many shares outstanding does Mineralys Therapeutics, Inc. have?
Mineralys Therapeutics, Inc. has 77,569,695 shares outstanding.
What happened to Mineralys Therapeutics, Inc.’s price movement after its last earnings report?
Mineralys Therapeutics, Inc. reported an EPS of -$0.66 in its last earnings report, beating expectations of -$0.739. Following the earnings report the stock price went up 0.37%.
Which hedge fund is a major shareholder of Mineralys Therapeutics, Inc.?
Currently, no hedge funds are holding shares in MLYS
Mineralys Therapeutics, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$44.57 (17.23% Upside)
$44.57 (17.23% Upside)
Blogger Sentiment
Bullish
MLYS Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 29.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $45.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 2.3%
Last 30 Days ▼ 2.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
147.55%
12-Months-Change
Fundamentals
Return on Equity
-63.21%
Trailing 12-Months
Asset Growth
5.41%
Trailing 12-Months
Company Description
Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
MLYS Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a positive outlook with significant advancements in clinical trials, financial stability, and preparation for regulatory approval. However, increased net loss, rising G&A expenses, and potential market competition are noted challenges.View all MLYS earnings summariesMLYS Stock 12 Month Forecast
Average Price Target
$44.57
▲(17.23% Upside)
Technical Analysis
Viking Therapeutics
―
Xenon
―
Apellis Pharmaceuticals
―
NewAmsterdam Pharma Company
―
Centessa Pharmaceuticals
―
Ownership Overview
42.32% Insiders
7.79% Mutual Funds
0.59% Other Institutional Investors
38.96% Public Companies and
Individual Investors